Thus, while effective suppression of IDH mutations in peripheral tumors or hematological malignancies can typically be confirmed based on a decrease in circulating 2-HG levels, plasma 2-HG levels in glioma patients are not elevated above the normal concentration [44]. The gene discussed is IDH2; the disease is central nervous system cancer.